Study says overweight people lost 35 to 52 pounds from newly approved diabetes drugs

Tirzepatide, sold under the brand name Mounjaro, has been studied in people without diabetes in three doses: 5, 10 and 15 milligrams. Obese or overweight participants who took the 5 mg dose lost an average of 35 pounds (16 kg), those who took the 10 mg dose lost an average of 49 pounds (22 kg), and participants who took the 15 mg dose lost the dose On average, 52 pounds (23.6 kilograms).

Co-author Dr. Anya Gastropov, co-director of the Yale Center for Weight Management, gave a briefing to the media.

Dr. said. Robert Gabbai, chief medical officer of the American Diabetes Association, spoke to CNN from the 82nd ADA Scientific Sessions in New Orleans, where the study findings were presented.

“The weight loss they experienced in this study was greater than what has been seen in previous studies of diabetics,” said Gabay, who was not involved in the study.

“The average range of weight loss for the people in this new study was 49 pounds — 49 pounds is a lot,” he said. “It’s the scale of weight loss we think is only possible through surgery.”

Overall, people without diabetes lost an average of 15% to 20.9% of their initial body weight over the 72-week period of the randomized, double-blind clinical trial, which was published Saturday in the New England Journal of Medicine. Participants who received a placebo lost between 2.4% and 3.1% of their body weight on average.
In comparison, studies of diabetics who used tirzepatide found that they lost an average of 15 percent of their initial body weight, Gabbay said.

“This is an unusual observation,” he said. “The effect of previous weight-loss drugs is less effective in people with diabetes, and we honestly don’t know exactly why.”

However, tirzepatide’s effect on people with diabetes remains “profound,” Gabbay said, “providing much more than the other tools we have.”

self-injection dose

For the new study, weekly injections of tirzepatide were tested in more than 2,500 people without diabetes who had a body mass index (BMI) greater than 30 or more than 27 BMI and had at least one weight-related health condition such as high blood pressure. High cholesterol or cardiovascular disease. A measure of a person’s height-to-weight ratio, a BMI of 25 or higher is considered overweight in adults.

Study says alternative sweeteners in your drinks can help with weight gain and diabetes risk

At the start of the study, participants had an average weight of 231 pounds (104.8 kg) and an average BMI of 38.

Gabai said the adults in the study injected themselves with terzepatide or a placebo once a week, using a “small pen-like device with a very fine needle.” “Prick that needle is less painful, for example, than prick their finger to measure their blood glucose.”

The people in the study also received counseling sessions to help them stay on a healthy diet with a daily deficit of 500 calories, as well as at least 150 minutes of physical activity each week. While that certainly helped, it doesn’t explain the amount of weight loss seen in the study, Gabay said.

“The kind of weight loss we see when people exercise and change their calorie intake is anywhere from 5% to 7%,” he said. “This study showed significantly greater weight loss, much higher than we would imagine with lifestyle changes.”

The most common side effects reported were nausea, diarrhea and constipation. Between 2.6% and 7.1% of participants discontinued treatment due to adverse events.

Moonjaro carries a boxing warning about thyroid tumors and should not be used by people with a family history of certain thyroid conditions.

Study says changing your diet can add up to 13 years to your life

“Obesity must be treated like any other chronic disease – with effective and safe approaches that target the underlying (causes) of the disease…These findings confirm that terzipatide may do just that,” said Gastropov of the Yale Center for Weight Management. In a press release for the American Diabetes Association.

“These findings are an important step forward in expanding potentially effective treatment options for obese people.”

Leave a Comment